Open in interactive viewer → charts, metric popovers & call review

Cibus: A $100 Million Scent, a $10.7 Million Cash Pile

The new CEO has recast Cibus as a direct-sales biofragrance story and a faster breeder—but rice is now a 2028 launch and the balance sheet still sets the clock.
CBUS · Earnings Call · 2026-11-12

The pivot: from royalties to scents

Cibus reported third-quarter 2026 on Nov. 12 with its stock down 44.1% over the prior 90 trading days and 52.7% below its July peak. The market cap is about $86 million. The call, however, was not a requiem. It was a rebranding. New CEO Craig Wichner spent most of his prepared remarks explaining Direct Breeding—a single-cell editing process that returns a customer's elite variety in 12 to 15 months—and recasting the business around two near-term revenue streams: biofragrance ingredients and rice traits. The biofragrance update was the most concrete. Management said its partner has approved the first two ingredients, that Cibus has initiated manufacturing for anticipated production runs, and that the partner has requested larger quantities of two additional scents. Peter Beetham then changed the size of the prize: “In August, we described a $20 million to $40 million peak annual revenue opportunity, we are now operating under a direct sales model rather than the royalty model we previously assumed. And on that basis... we believe our biofragrance business could represent up to approximately $100 million in peak annual revenue.” — Peter Beetham, Co-Founder, President · 2026-11-12 The shift from a royalty model to a direct sales model is real. Carlo Broos said the company will use a contract manufacturer, so there is no capital expenditure on Cibus, and “gross margins can be around 50% and can grow maybe even up to 70% going forward when you hit economies of scale.” — Carlo Broos, Chief Financial Officer · 2026-11-12 But the timing is still formulation-first, purchase-order-second. Wichner was explicit: “once we get formulation wins in essence, then we get a purchase order and that converts into revenue.” — Craig Wichner, Chief Executive Officer · 2026-11-12 That is not a 2027 revenue ramp; it is a 2027 possibility. Third-quarter revenue was $0.8 million, and nine-month revenue was $3.5 million. The $100 million is peak annual revenue from eight ingredients, not a guide.

The vocabulary changed; the cash clock did not

The call's most interesting tell is what disappeared. In prior quarters, Cibus sold investors on a Trait Machine—a royalty machine for seed companies. That phrase is absent from the current top keywords. In its place is Direct Breeding, backed by single-cell editing, elite seed varieties, and the promise of multiple edits at once. The new language is better product marketing. It also resets the story away from the old royalty timeline. The new proof points are Crystal Crop in Indian mustard and Light Leaf Spot in U.K. winter oilseed rape. Both are partner- or grant-funded programs. Wichner framed India as a national mission to double oilseed harvest by 2030-31, with genome editing named as a tool. That is a large long-term opportunity, but the work has just started: the first step is taking a single cell from Crystal Crop's mustard varieties and growing it back into a whole plant. The U.K. program is on schedule, with edited plants going through a cold period now. Neither is a near-term royalty stream. They are evidence that the platform works, not evidence that it monetizes soon. Rice is supposed to be the bridge. Management still describes a roughly $200 million annual addressable royalty opportunity across an estimated 5 million to 7 million peak acres in Latin America. But the timeline moved. In May 2026, Peter Beetham said:

The difference with Interoc in Latin America is the chemical registration is going concurrently. And we see a clear path to both that and the seed being ready in the latter half of 2027.

Peter Beetham, Co-Founder, Interim Chief Executive Officer, President and COO · 2026-05-14
On this call, the language was “targeting initial commercial launch as early as 2028.” — Peter Beetham, Co-Founder, President · 2026-11-12 The U.S. is now 2029 or 2030, tied to Albaugh's herbicide registration. A one-year slip in a crop trait launch is not fatal, but for a company with one quarter of cash, it is the whole story. Europe is further out still: the European Union rules are in a two-year implementation period running to 2028, and the implementing acts will decide how quickly a pod shatter or disease-resistance trait can be submitted.

The balance sheet sets the clock

The cash math is unforgiving. Cibus ended September with $10.7 million of cash. Third-quarter cash used in operating activities was $9.3 million, and management still expects to exit 2026 at roughly a $35 million annualized net cash usage rate. That is actually a drift from the prior target: in May, Carlo Broos said the company was “working towards that target to be on a net annualized burn of $30 million or less.” — Carlo Broos, Interim Chief Financial Officer · 2026-05-14 The last filed balance sheet showed effective net cash of $20 million, down 45% year over year, and the filed cash runway at 2.2 quarters. By the third-quarter call, the runway had shortened to early first-quarter 2027.

Taking into account the impact of implemented cost-saving initiatives and without giving effect to potential financing transactions... we expect that existing cash and cash equivalents are sufficient to fund planned operating expenses and capital expenditure requirements into early in the first quarter of 2027, though we expect to need to raise additional capital in the near term.

Carlo Broos, Chief Financial Officer · 2026-11-12
The cost cuts are real. R&D expense fell to $7.9 million from $10.8 million, and total operating expenses declined by about $2.7 million year over year. The filed R&D expense was $9 million, down 30% year over year. But the net loss was still $21.9 million, including $9.8 million of noncash royalty liability interest to related parties. That interest does not consume cash, but it does consume equity. Liabilities to assets stood at 95.3%. A financing is not a tail risk; it is the base case.

What the market is saying

Wichner closed with a comparison to Vylor, the seed and genetics business spun out of Corteva that went public on Oct. 1 at a roughly $48 billion market cap. His point was that the market now has a public comp for gene editing in agriculture, and that Cibus's technology is faster and cheaper because it does not sell seeds or chemicals. It is a fair argument in a five-year window. It is not an argument the market is accepting today. Cibus's own market cap is about $86 million, and the stock is in a deep drawdown. The global tape offers no rescue. Cibus's fresh keywords—United Kingdom, mustard, petri dish, Vylor—are company-unique, not part of a sector-wide wave like AI data centers or tariff refunds. That cuts both ways: there is no crowded trade to lean on, but there is also no macro tide lifting the story. The conclusion is not that Cibus is a fraud or that Direct Breeding does not work. The conclusion is that this report changed the narrative without changing the financial clock. The company has a real platform, a new CEO with a coherent story, and a larger biofragrance ambition. It also has $10.7 million of cash, a launch timeline that slipped to 2028, and a financing need that will likely be priced before the first rice royalty is earned. The next catalyst is not a harvest. It is a capital raise.